Navigation Links
Gene therapy 'trains' immune system to destroy brain cancer cells and reverses behavioral deficits

LOS ANGELES (EMBARGOED UNTIL: 4:30 p.m. EST /February 19, 2008) A new gene therapy approach that attracts and trains immune system cells to destroy deadly brain cancer cells also provides long-term immunity, produces no significant adverse effects and -- in the process of destroying the tumor -- promotes the return of normal brain function and behavioral skills, according to a study conducted by researchers at Cedars-Sinai Medical Centers Board of Governors Gene Therapeutics Research Institute.

The study was conducted in a recently developed laboratory rat model of glioblastoma multiforme (GBM) that closely simulates outcomes in humans and supports the translation of this procedure to human clinical trials later this year. Results of the study are described in the Feb. 19 issue of Molecular Therapy, the journal of the American Society for Gene Therapy.

These findings appear to be a significant milestone in creating an effective treatment for glioblastoma multiforme, said Maria Castro, Ph.D., co-director of the Board of Governors Gene Therapeutic Research Institute and principal investigator of the study. This therapy significantly improved survival rate, induced long-lasting systemic anti-tumor immunity, and resolved the neuropathological abnormalities caused by the tumors, which has been a stumbling block to many promising treatments.

The article documents the gene therapys effectiveness in killing GBM cells and launching an effective and sustained systemic immune response. It also focuses on the safety of the therapy as well as its ability to restore normal brain function and reverse behavioral deficits caused by large tumors.

Humans with GBM often suffer behavioral abnormalities that affect concentration, memory and balance. In the animal studies, rats exhibited abnormal rotational movements. The research team found that as the tumors grew, they displaced and compressed nerve terminals and impulse-conducting axons. But long-term survivors who had received the gene therapy did not have long-term injury or behavioral impairment resulting from the tumor or the treatment.

Tumor growth causes behavioral deficits, but even treatments, such as chemotherapy and radiation therapy, can cause learning disabilities and other cognitive problems. In our animal study, this therapy eliminated the tumor mass and reversed the deficits that were caused by the tumor, said Pedro Lowenstein, M.D., Ph.D., co-principal investigator on the study and director of the Board of Governors Gene Therapeutics Research Institute.

Glioblastoma multiforme, the most common and deadly type of brain cancer, usually claims the lives of victims within six to 12 months of diagnosis. It is extremely difficult to treat for a variety of reasons. GBM tumors grow rapidly, often becoming large before a diagnosis is made. Also, cells readily infiltrate neighboring tissue and migrate to other areas, hampering complete surgical removal. Chemotherapy and radiation therapy are unable to eliminate all residual GBM cells, which frequently become resistant to the treatments.

The blood-brain barrier also prevents chemotherapy from effectively reaching tumor cells, and key cells needed to launch and sustain a systemic anti-tumor immune response dendritic cells, or antigen-presenting cells do not naturally occur within the brain.

The gene therapy approach developed at Cedars-Sinai sidesteps all of these challenges. The researchers used a virus stripped of its disease-causing genes as a vehicle to deliver two therapeutic proteins directly into the tumor cells. One protein, FMS like tyrosine kinase 3 ligand (Flt3L), drew dendritic cells into the brain. Another protein, herpes simplex virus type 1 thimidine kinase (HSV1-TK), combined with the antiviral gancyclovir (GCV), killed tumor cells.

Dendritic cells clean up debris from dying cells and in the process alert immune system cells of the existence of foreign entities, or antigens in this case, GBM cells. Newly educated immune system cells then swarm to the tumor cells to destroy them.

In an earlier study, the Cedars-Sinai researchers used HSV1-TK and GCV alone to treat GBM and found that about 20 percent of the animals survived, compared to controls. By adding the dendritic-cell inducing Flt3L, the survival rate jumped to about 70 percent. Systemic immune activity was sustained, even fending off a re-challenge with additional tumor cells. In this study, the researchers at the BOG-GTRI reported that this therapy could also revert behavioral abnormalities caused by the growing tumor in the brain.

In the fairly near future, this combined gene therapy may work synergistically with current therapies, including chemotherapy and radiation therapy, allowing doctors to reduce dosages and avoid side effects, Dr. Castro said. But with the safety, effectiveness and curative potential seen in these studies, we are hopeful that gene therapy for GBM could become the new standard of care.


Contact: Simi Singer
Cedars-Sinai Medical Center

Related medicine news :

1. Merging discovery with therapy: Second generation memory care debuts
2. Study Shows New Therapy Opens Blocked Fallopian Tubes, Returns Fertility Without Surgery
3. Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
4. Scientists move towards stem cell therapy trials to mend shattered bones
5. Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too
6. Viral Therapy Slows Pediatric Tumors in Mice
7. HIV persists in the gut despite long-term HIV therapy
8. GPS for the Prostate: System Keeps Radiation Therapy on Target
9. Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
10. Stop & Shop Alerts Customers to Voluntary Recall of Chattem Icy Hot Heat Therapy Products
11. Giant Food Alerts Customers to Voluntary Recall of Chattem Icy Hot Heat Therapy Products
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... optimization of adjunctive imaging is the focus of numerous abstracts accepted for presentation ... 29-December 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. (December ... the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis ... celebrates exceptional special needs providers that excel in synthesizing the areas of clinical ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), a ... health arenas, is pleased to announce that VIP Care Services, a Caprock Health ... the ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , users ... over customization, the possibilities are truly endless, all with a click of a mouse. ... vertical flip, horizontal flip, depth of field and more, all within Final Cut Pro ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced today ... status from Cisco. This designation recognizes Tympani as having fulfilled the training requirements ... targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
(Date:12/1/2015)... , Dec. 1, 2015 Pharma Tech ... Top 10 Clinical Data Management Solution Providers - ... a distinguished panel comprising CEOs, CIOs, VCs, analysts, and ... the illustrious list of top 10 clinical data management ... article on pages 14 and 36 respectively). ...
(Date:12/1/2015)... de diciembre de 2015  AccuTEC Blades, ... de precisión, develó hoy un nuevo logo ... marca. El nuevo logo destaca la experiencia ... ingeniería de productos con cuchillas donde "el ... --> ...
Breaking Medicine Technology: